Active Not Recruiting PHASE2 INTERVENTIONAL 4-arm NCT06601504

Study of HMPL-760 Plus R-GemOx Versus Placebo Plus R-GemOx in Relapsed/Refractory DLBCL

A Phase II Randomized, Controlled Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of HMPL-760 Plus R-GemOx Versus Placebo Plus R-GemOx in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma(R/R DLBCL)

Sponsor: Hutchmed

Conditions Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Interventions HMPL-760 placebo planned dose 1 HMPL-760 placebo planned dose 2 HMPL-760 planned dose 1 HMPL-760 planned dose 2 R-GemOx

Updated 3 times since 2024 Last updated: Jun 3, 2025 Started: Nov 5, 2024 Primary completion: May 12, 2026 Completion: Nov 12, 2026

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Relapsed/Refractory Diffuse Large B-Cell Lymphoma, this trial is ongoing. The trial is conducted by Hutchmed and has accumulated 3 data snapshots since 2024. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

3 versions recorded

Jul 2025 — Present [monthly]

Active Not Recruiting PHASE2

Status: Recruiting → Active Not Recruiting
Dec 2024 — Jul 2025 [monthly]

Recruiting PHASE2

Status: Not Yet Recruiting → Recruiting
Oct 2024 — Dec 2024 [monthly]

Not Yet Recruiting PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Hutchmed

Data source: Hutchmed

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Changsha, China , Chengdu, China , Fuzhou, China , Guangzhou, China , Harbin, China , Jinan, China , Nanchang, China , Nanning, China , Shanghai, China , Shenyang, China and 3 more locations